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The Myocyte Enhancer Factor 2C (MEF2C) transcription factor plays a critical role in skeletal muscle differentiation,
promoting muscle-speciﬁc gene transcription. Here we report that in proliferating cells MEF2C is degraded in mitosis by
the Anaphase Promoting Complex/Cyclosome (APC/C) and that this downregulation is necessary for an efﬁcient
progression of the cell cycle. We show that this mechanism of degradation requires the presence on MEF2C of a D-box
15 (R-X-X-L) and 2 phospho-motifs, pSer98 and pSer110. Both the D-box and pSer110 motifs are encoded by the
ubiquitous alternate a1 exon. These two domains mediate the interaction between MEF2C and CDC20, a co-activator of
APC/C. We further report that in myoblasts, MEF2C regulates the expression of G2/M checkpoint genes (14–3–3g,
Gadd45b and p21) and the sub-cellular localization of CYCLIN B1. The importance of controlling MEF2C levels during the
cell cycle is reinforced by the observation that modulation of its expression affects the proliferation rate of colon cancer
20 cells. Our ﬁndings show that beside the well-established role as pro-myogenic transcription factor, MEF2C can also
function as a regulator of cell proliferation.
Introduction
MEF2 proteins are members of the MADS (MCM1, Aga-
mous, Deficiens and SRF) family of transcription factors that in
25 vertebrates comprises 4 members, MEF2A-D. All MEF2 proteins
share an N-terminal MADS box and an adjacent MEF2 domain
that are required for MEF2 proteins homo- and hetero-dimeriza-
tion and high-affinity DNA binding to the consensus sequence
(C/T TA(A/T)4TAG/A) within the regulatory regions of target
30 genes. The C-terminal regions of MEF2 factors contain tran-
scription activation domains and are subject to complex patterns
of alternative splicing. MEF2s are expressed in many tissues and
organs where they control the activation of their differentiation
programs.1 MEF2 proteins are highly expressed in skeletal mus-
35 cle where they play a pivotal role in terminal differentiation but
they are unable to activate myogenesis alone; instead, these fac-
tors work in concert with the MYOD family of myogenic deter-
minants, synergistically promoting myofiber differentiation.2-4
Genetic studies in mouse and zebrafish have shown that among
40 Mef2 genes, Mef2c plays a unique role in the late phases of myo-
genesis, where it is essential for myofibers maturation.5,6 Despite
the well established role iN-terminal differentiation, Mef2c tran-
scripts and protein are already detected in primary mouse
myoblasts.7,8 To date most models suggest that MEF2 proteins
45exhibit no specific functions in myoblasts, but exist to “prime”
muscle cells for differentiation when the environmental condi-
tions become permissive (for example cessation of cellular prolif-
eration signals). Consequently, we and other have proposed
several mechanisms contributing to the silencing of the pro-
50myogenic activity of MEF2C in proliferating myoblasts. Mecha-
nisms mediating this negative regulation include post-transla-
tional modifications leading to increased physical interaction
with inhibitors such as class II HDACs and PIN1, reduced DNA
binding capabilities and/or protein stability.9-11 Besides, in verte-
55brates, a fundamental role in MEF2C activity regulation is played
by alternative splicing processes.12-14 In mammals 3 major exons
are alternatively spliced in MEF2A, MEF2D or MEF2C: the 2
mutually exclusive exons a1 and a2, a short exon b and an exon
g, which is only spliced in some MEF2C gene transcripts. In
60muscle cells the alternate inclusion in Mef2c transcripts of the
ubiquitous a1 or muscle-specific a2 exon has a particular rele-
vance in regulating the pro-myogenic activity of the encoded pro-
tein.15,16 The recent observation that MEF2Ca1, present in
proliferating myoblasts, is devoid of myogenic activity suggests
65that this “priming model” cannot be applied to this splice variant
and indicate some novel functions of MEF2C in myoblasts.
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Indeed, in other cell types, Mef2c stimulates proliferation and
regulate the expression of growth-related genes.17-22 Further-
more, recently Mef2c has been shown to regulate cell cycle
70 related-genes in muscle cells.23 Therefore, in the attempt to
investigate this unexplored activity, we found that the level of
MEF2C protein fluctuates during the cell cycle and we describe a
novel mechanism by which the Anaphase Promoting Complex/
Cyclosome (APC/C) ubiquitin ligase controls MEF2C abun-
75 dance. The functional relevance of this mechanism during the
cell cycle is suggested by the observation that ectopic expression
of a MEF2C mutant, resistant to APC/C-dependent degrada-
tion, impairs entry into mitosis and cell proliferation.
Furthermore, modulation of Mef2c expression in colon cancer
80 cells affects their proliferation rates. We also demonstrate that
MEF2C, directly or indirectly, controls the expression of genes
that regulate G2/M transition (Gadd45B, P21 and 14.3.3 g)24-26
and CYCLIN B1 sub-cellular localization. In summary, we pres-
ent evidence that MEF2C plays a role in the transcriptional con-
85 trol of cell cycle-related genes and its degradation in mitosis
contributes to the G2/M checkpoint inactivation in growing
myoblasts.
Results
The ubiquitin-proteasome system (UPS) regulates MEF2C
90 protein level during the cell cycle
MEF2C function in terminal differentiation of skeletal muscle
has been well established, on the contrary little is known about its
role in proliferating muscle cells. To investigate this issue, we
used the C2 mouse cell line, derived from adult muscle cells, the
95 satellite cells.27 C2 cells proliferate as mononucleated myoblasts
in high-serum medium, theN-terminally differentiate to multi-
nucleated myotubes upon serum withdrawal. As shown in
Figure 1A, MEF2C is already present in C2 myoblasts where
also MYOD is expressed, as previously described.28 MEF2C level
100 raises upon terminal differentiation, concomitantly with the
expression of MYOSIN HEAVY CHAIN (MyHC) and MYO-
GENIN, a well established MEF2C target.29 To start evaluating
a potential role of MEF2C in growing cells, we determined if the
cell cycle might have an impact on MEF2C protein level, as it is
105 reported for several genes that influence cellular proliferation. To
address this issue, we synchronized C2 muscle cells in G0/G1, S,
G2 and M phase. Western blot analysis confirmed that C2 cells
were highly synchronized in our experimental conditions, as
attested by the appearance of CYCLIN A as DNA synthesis pro-
110 ceeds and of Histone H3 phosphorylated on Serine 10 during
mitosis (pH3(Ser10), Fig. 1B). The distribution of cells in the
different phases was measured by flow cytometry analysis after
propidium iodide staining (Fig. 1B lower table, Fig. S1A). To
analyze the expression of Mef2c in the course of the cell cycle,
115 proteins and mRNA extracts were prepared from synchronized
myoblasts. Western blot analysis revealed that the level of
MEF2C protein is high in G0/G1, S and G2 phases, whereas it
is largely decreased and exhibits a lower electrophoretic mobility
in M phase cells compared to the other phases of the cell cycle
120(Fig. 1B). To further verify the efficacy of our synchronization
protocol of C2 myoblasts, we also examined the protein level of
the key myogenic regulators MYOD and MYF5. As shown in
Figure S1B, the expression pattern of MEF2C during the cell
cycle resembles that already described for MYF5,30-32 whereas, as
125expected, MYOD protein level was very low in G0/G1 and only
slightly reduced in M phase cell extracts.33-35 The mitotic down-
regulation profile of endogenous MEF2C was also observed in a
non muscle cell line, the mouse NIH-3T3 fibroblasts (Fig. S1C).
C2 synchronized extracts were further analyzed by quantitative
130PCR (RT-qPCR). While the amounts of MEF2C protein signifi-
cantly decreased during the M phase, the level of Mef2c mRNA
was higher if compared to the other phases suggesting that post-
transcriptional mechanisms must be involved in the downregula-
tion of MEF2C. Treatment of asynchronous C2 cells with the
135proteasome inhibitor MG132 prevented MEF2C protein down-
regulation in a dose-dependent manner (Fig. 1D), suggesting
that its decrease in mitosis is at least partially due to proteasome-
dependent degradation. Proteasome targets are usually modified
by the covalent addition of poly-ubiquitin chains. To test
140whether MEF2C is poly-ubiquitinated, C2 cells were co-trans-
fected with FLAG-MEF2C and HA-ubiquitin expression plas-
mids. After inhibition of the proteasome, we
immunoprecipitated FLAG-MEF2C proteins and observed by
Western blot with the anti-HA antibody the presence of poly-
145ubiquitinated forms of MEF2C (Fig. 1E). When HA-ubiquitin
was transfected with an empty vector (EV), no product was
detected. Overall these data indicate that in myoblasts MEF2C
undergoes an increased protein degradation in mitosis and that
this downregulation is due to the UPS system.
150Role of phosphorylation in MEF2C degradation
We next explored the regulatory mechanism that triggered
MEF2C degradation. Our data indicate that MEF2C protein
decreases when cells pass through mitosis, whereas mRNA
remains unaffected, and that the residual mitotic MEF2C protein
155has a lower electrophoretic mobility. Therefore we wanted to
determine if a mitosis-specific post-translational modification
might be necessary for MEF2C degradation. We considered that
phosphorylation of Ser98 and Ser110 were likely candidates as
modifications involved in MEF2C degradation, as phospho-
160Ser98 and phospho-Ser110 are binding sites for PIN1, a peptidyl
prolyl cis-trans isomerase that regulates MEF2C protein stabil-
ity.10 Notably, Ser110 is located within a domain encoded by the
a1 exon, that is included in Mef2c transcripts alternatively to
exon a2 (see Fig. 2A). In agreement with previous data,15 our
165results indicate that proliferating myoblasts express only the tran-
script encoding the MEF2C a1 isoform, containing both Ser98
and Ser110, as determined by reverse transcription PCR (RT-
PCR), using 2 common primers (Fig. 2A) that give 2 isoform-
specific amplicons with different electrophoretic mobilities and
170that are differently susceptible to enzymatic restriction (Fig. S2).
We evaluated the level of phosphorylation of these serines during
the cell cycle using 2 antibodies that recognize MEF2C when
phosphorylated on Ser98 (pSer98 MEF2C) or Ser110 (pSer110
MEF2C). As shown in Figure 2C, the variations of the signals of
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175 phospho-Ser110 reflects the fluctuations of the MEF2C protein
during the cell cycle (compare to Fig. 2C), indicating a steady
state level of MEF2C phosphorylation on this residue through-
out the cell cycle. By contrast, in mitotic cells Ser98 phosphoryla-
tion is most abundant although the global level of MEF2C
180 protein is the lowest (Fig. 2C and Fig. 1B). Densitometric quan-
tification revealed a fold7- increase of pSer98 MEF2C signal
normalized to the total amount of MEF2C protein in mitosis
compared to asynchronous cells (Fig. 2C, lower panel). To deter-
mine the protein kinase(s) that regulate Ser98 and Ser110 phos-
185phorylation, we carried out a kinase phosphorylation profiling
that revealed a preferential ability of the peptide containing
Ser110 to act as a substrate for the CDK5/p35 and CDK6/
CycD1 protein kinases (Fig. S3A). On the contrary the peptide
Figure 1.MEF2C protein level is downregulated in mitosis and is targeted for degradation by the Ubiquitin-Proteasome Pathway. (A) MEF2C is expressed
in proliferating myoblasts. Total protein extracts from C2 growing myoblasts (Mb) or differentiated myotubes (Mt) were analyzed by Western blot with
antibodies against myosin heavy chain (MyHC), MYOGENIN, MYOD and MEF2C. Actin was used as loading control. (B) MEF2C protein level decreases in
mitotic cells. C2 cells were grown asynchronously in high serum medium (Asyn), arrested in G0/G1 by incubation in methionine-depleted medium, syn-
chronized in S by treatment with aphidicoline or incubated with Nocodazole before shake off treatment to generate a mitotic fraction (Shake off fraction;
M) and a non-mitotic fraction (adherent; G2). Cell lysates obtained from synchronized cell populations were analyzed by Western blot assay with anti-
body against MEF2C. Antibodies speciﬁc for CYCLIN A and histone H3 phosphorylated on Ser10 (pH3(Ser10)) were used to verify the level of synchroniza-
tion in S and M phases obtained with the treatments. Vinculin was used as loading control. DNA content was assessed by ﬂow cytometry analysis,
percentage of distribution in G0/G1, S and G2/M phase are reported (lower panel). (C) Analysis of Mef2C transcripts during the cell cycle. Total RNA was
isolated from synchronized populations obtained as in A and Mef2c mRNA level was quantiﬁed by RT-qPCR. The ratio between Mef2c and Gapdh tran-
scripts was calculated in each synchronized cell population. Value obtained for asynchronous C2 was arbitrarily set equal to 1. Histograms report the
mean of 2 independent experiments § SEM. * and ** represent P-values  0.05 and  0.01 respectively. (D) MEF2C is degraded by the proteasome. C2
proliferating myoblasts were incubated with increasing concentrations of the proteasome inhibitor MG132 (25 mM or 50 mM) from a stock in DMSO, the
control sample received an equivalent volume of DMSO. After 4 hours of treatment cells were harvested and protein extracts were analyzed by Western
blotting with anti-MEF2C speciﬁc antibody. Vinculin was used as a loading control. Lower panel shows the results of the densitometric quantiﬁcation of
the signals obtained with the anti-MEF2C antibody normalized for the total amount of protein. The quantity of MEF2C protein in MG132 treated cells is
expressed relative to the quantity of MEF2C in the control sample (DMSO) taken as 1. (E) MEF2C is poly-ubiquitinated in proliferating myoblasts. CoIP
and Western blot assays of lysates from C2 cells transiently transfected with vectors coding for FLAG-MEF2C and increasing amounts of HA-ubiquitin
(HA-Ub) or Empty Vector (EV) as control. Thirty hours after transfection cells were treated with MG132 and then harvested. Anti-FLAG antibody was used
for immunoprecipitation (IPaFLAG), anti-FLAG and anti-HA for Western blot detection of total Input and of immunoprecipitated proteins (IPaFLAG).
Western blot results shown in B, D and E are representative of 2 independent experiments showing similar proﬁles.
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containing Ser98 was not efficiently phosphorylated by any tested
190 kinases. The proximity of Ser98 and Ser110 led us to examine
their importance as reciprocal “priming” sites. To verify this
hypothesis we singularly substituted each of the 2 serines with
alanine and assayed the effects of these mutations on the phos-
phorylation of the wild type residue in proliferating cells. As
195 shown in Figure S3B, mutation on Ser98 did not alter the effi-
ciency of Ser110 phosphorylation whereas Ser98 phosphoryla-
tion is strongly impaired (35% less) when Ser110 is substituted
with an Alanine. This data suggest a mechanism whereby phos-
phorylation of MEF2C on Ser110 is necessary for the subsequent
200 Ser98 phosphorylation by a yet unknown mitotic kinase. The
hypothesis of a M phase-specific phosphorylation of MEF2C on
Ser98 is reinforced by the observed co-localization of pSer98
MEF2C in cells that are positive for Histone H3 phosphorylated
on Ser10 (Fig. S4).
205Next we observed that phosphorylation of Ser98 and Ser110
promotes MEF2C poly-ubiquitination, given that the formation
of MEF2C-Ubiquitin conjugates is strongly impaired with the
protein mutated on the phosphoacceptor sites (MEF2C 2SA)
(Fig. 2D). Coherently with these findings, we found that the lack
210of MEF2C phosphorylation on Ser98 and Ser110 increases the
stability of MEF2C in proliferating cells: in cycloheximide
(CHX)-treated COS cells the half-lives of single (S98A, S110A)
or double (2SA) not phosphorylable MEF2C mutants are
increased if compared to that of the wild type protein (half life
2158 hours) (Fig. 2E). Altogether our data indicate that a G1 phase
kinase, likely CDK6/CycD1, phosphorylates MEF2C on
Figure 2. Ser98 phosphorylation of MEF2C peaks in mitosis, triggers poly-ubiquitination of the protein and reduces its stability. (A) Schematic of the
MEF2C isoforms in the exon 3 region, with the location of the primers used to detect the alternate a1 and a2 exons indicated (arrows). The amminoacid
sequences of the a exons of the mouse protein are indicated below. The positioning of Ser98 and Ser110 phosphoacceptor sites in a1 exon (and the res-
idue equivalent to Ser98 in a2 exon) are highlighted in red. (B) Exclusive inclusion of the a1 exon in Mef2c transcripts in growing myoblasts. Total RNA
was isolated from C2 myoblasts (Mb) or C2 cells that were differentiated for various lengths of time (0–72h). Exon expression was detected by RT-PCR
using common primer (indicated in A) located on exons 2 and 4 that give rise to ampliﬁcation products with different electrophoretyc mobility. Ampliﬁ-
cation of plasmid vectors containing the murine cDNAs of the MEF2C a1 and a2 splice variants were used as controls of the correct size of expected
amplicons .a1 and a2 sample lanes). Rplp0 was used as endogenous control. (C). MEF2C is highly phosphorylated on Ser98 in mitotic cells. Cell lysates
of asynchronous (Asyn) or synchronized cells were analyzed by Western blot with polyclonal antibodies that recognize the phosphorylated Serine 98
(pSer98) or Serine 110 (pSer110) of MEF2C. Vinculin was used as loading control. The levels of Ser98 and Ser110 phosphorylation, evaluated by densito-
metric scanning, were normalized to the quantity of MEF2C protein (see Fig. 1B). In the histogram below are reported the phosphorylation grades of
the 2 residues in synchronized cells, expressed relative to the value obtained in asynchronous cells, taken as 1. (D). Ser98 and Ser110 phosphorylation
triggers MEF2C poly-poly-ubiquitination. C2 myoblasts were transiently transfected with expression vectors for HA-ubiquitin and FLAG-tagged wild type
(WT) or not phosphorylable MEF2C 2SA mutant where Ser98 and Ser110 are substituted with alanines. Anti-FLAG antibody was used for immunoprecipi-
tation (IPaFLAG), anti-HA for Western immunoblot detection (IB). (E) The non-phosphorylable MEF2C mutant proteins on Ser98 and Ser110 are more sta-
ble than the wild type protein. FLAG MEF2C wild type or mutated singularly on Ser98 (S98A), Ser110 (S110A) or both phosphoacceptor sites (2SA) were
overexpressed in COS1 cells. After 36 h, protein synthesis was blocked with cycloheximide, the amount of FLAG MEF2C remaining at different times was
checked by Western blot. Protein loading was controlled by anti- vinculin staining. The intensity of FLAG signal was quantiﬁed by densitometric analysis.
The graph reports average of the intensity of MEF2C signals, relatively to the not treated sample (CHX 0h), of 2 independent experiments. Bars represent
SEM. Western blot results reported in C and D are representative of 2 independent experiments that showed similar proﬁles.
4 Volume 14 Issue 10Cell Cycle
Ser110, priming the protein for the sub-
sequent mitosis-specific phosphorylation
on Ser98 that ultimately promotes its
220 degradation through the UPS.
CDH1 or CDC20 mediate the
degradation of MEF2C
The finding that the level of MEF2C
protein decreases during mitosis, suggest
225 that its degradation might be mediated
by APC/C, an ubiquitin ligase complex
that is responsible for degradation of sev-
eral protein during this phase of the cell
cycle. The activity of APC/C is con-
230 trolled by 2 related activators, CDC20
and CDH1, that contain a C-terminal
WD40 repeat domain, their main func-
tion being the recruitment of substrates
to APC/C.36 To verify our hypothesis,
235 we first tested if MEF2C physically inter-
acts with CDC20 and CDH1. To this
aim, HEK293T cells were transfected
with FLAG-MEF2C wild type or the
non-phosphorylable FLAG-MEF2C
240 2SA mutant and HA-tagged CDC20 or
CDH1, the whole cell extracts were
immunoprecipitated with anti-HA, and
the interaction revealed by Western blot-
ting with anti-FLAG (Fig. 3A). MEF2C
245 was clearly detected in the purified prep-
aration of both CDC20 and CDH1, but
not in the control immunoprecipitation
sample (EV). We observed a slight
reduction in the efficiency of association
250 between CDC20 and the 2SA mutant,
suggesting that the MEF2C/CDC20
interaction involves the phosphorylation
of Ser98 and Ser110. We then tested
whether the modulation of CDC20 and
255 CDH1 expression could affect the levels
of MEF2C protein wild type or mutated.
In C2 proliferating cells we observed that
the level of exogenous MEF2C decreased
when either CDH1 (90% less protein
260 compared to the control, Fig. 3B right
panel) or CDC20 (80% of decrease)
over-expression was induced. Further-
more the accumulation of the MEF2C
2SA mutant (30% of decrease) upon
265 ectopic expression of CDC20 indicates
that phosphorylation of Ser98 and
Ser110 is required for rapid degradation
of MEF2C by APC/CCDC20 but not by
APC/CCDH1 (Fig. 3B). As a control, we
270 found that SKP2, a known substrates of
APC/CCDH137,38 was down-regulated
Figure 3.MEF2C protein level is controlled by CDC20 or CDH1, depending on the phosphorylation of
Ser98 and Ser110. (A). MEF2C physically interacts with CDC20 and CDH1. Co-immunoprecipitation
analysis of Hek293T cells transiently transfected with empty vector (EV) or HA-tagged vectors coding
for CDC20 and CDH1 along with FLAG-MEF2C WT or 2SA. 48 hours aftertransfection, cells were
treated with MG132 and harvested. Total protein extracts (Input) were incubated with protein A
beads conjugated with anti-HA antibody. Left: input. Right: immunoprecipitated proteins: FLAG-
tagged MEF2C was detected by Western blotting with anti-FLAG antibody. Vinculin was used as a
loading control. Asterisk (*) indicates non-speciﬁc bands. (B) MEF2C expression is reduced by CDC20
and CDH1 overexpression, CDC20 dependent degradation relies on pSer98/pSer110 phosphoryla-
tion. C2 proliferating myoblasts were co-transfected with an empty vector (EV) or HA-tagged CDC20
and CDH1 vectors along with phosphorylable (WT) or not-phosphorylable (2SA) MEF2C. Cell extracts
were analyzed by Western blotting with antibodies against FLAG and HA. Vinculin was used as load-
ing control. The histogram (right panel) reports the densitometric quantiﬁcation of MEF2C protein
level (FLAG signal) normalized to the total amount of protein expressed relatively to the quantity of
protein in the control sample, taken as 1. Histograms show means § SEM of 3 independent experi-
ments. ** represent P-values  0.01. (C) RNAi knockdown of Cdc20 and/or Cdh1 results in an accumu-
lation of MEF2C. Asynchronous C2 cells were transfected with a control siRNA (siCTRL) or a pool of
siRNAs targeting Cdh1 (siCdh1, left panel) or Cdc20 (siCdc20, middle panel) mRNAs and analyzed
72 hours later. Alternatively C2 cells transfected with siCdc20 were treated over-night with Nocoda-
zole after 36 hours from transfection (left panel). Protein extracts were analyzed by Western blotting
with antibody against MEF2C, CDH1, CDC20 and histone H3 phosphorylated on Ser10, a marker of
the M phase. Vinculin was used as loading control. The results of the Western blot shown in A and C
are representative of 2 independent experiments that gave similar proﬁles.
www.tandfonline.com 5Cell Cycle
upon ectopic expression of CDH1 but not CDC20, as shown in
Figure S5. To further confirm that APC/CCDC20 and APC/
CCDH1 are required for degradation of endogenous MEF2C, we
275 inhibited their activities by siRNA. Silencing of both Cdc20 and
Cdh1 transcripts resulted in an increase of the endogenous
MEF2C level (Fig. 3C). We next tested whether CDC20 is
required for MEF2C degradation in mitosis. For this purpose,
we silenced Cdc20 in C2 cells arrested in prometaphase with
280 Nocodazole. As expected, MEF2C protein was downregulated in
mitosis in the control sample (Fig. 3D siCTRL). In contrast,
silencing of Cdc20 in nocodazole treated cells prevents MEF2C
mitotic degradation, restoring a protein level comparable to that
of asynchronous cells. Overall our results indicate that APC/
285 CCDC20 is responsible for the degradation of phosphoSer98
MEF2C in mitosis.
D-box, pSer98 and pSer110 motifs are required for
CDC20-dependent degradation of MEF2C
Previous studies revealed that APC/C recognizes sequence rec-
290 ognition motifs including a Destruction-box (RXXL; D-box)39
and/or a KEN-box (KEN).40 Since our results indicate that
MEF2C is a target of APC/C, we tried to identify degradation
signals in MEF2C. By sequence analysis, no KEN-boxes were
found in the MEF2C a1 isoform expressed in proliferating mus-
295 cle cells. On the contrary we identified one putative conserved
D-box motif in the amminoacidic sequence encoded by a1 exon,
proximal to the Ser98 and Ser110 residues (Fig. 4A). Indeed we
found that the CDC20-dependent degradation of the D-box
deleted mutant was lower than that of wild-type MEF2C
300(Fig. 4B, lane 5 compared to lane 2). When both D-box and
phosphoacceptor sites were mutated, the protein level was almost
completely stabilized (Fig. 4B, lane 11). Similar results were
obtained using the MEF2C 2SA mutant protein where the D-
box arginine and leucine were replaced by alanines (2SA D-box
305MUT) (Fig. S6A). Furthermore we also observed that the
MEF2C 2SA D-box deleted protein interacts less efficiently with
CDC20 (Fig. S6B). On the contrary either the phosphoacceptor
sites or the D-box are not required for the CDH1-dependent
degradation (lanes 3, 6, 9 and 12). Taken together, a model
310emerges in which MEF2C establishes a multivalent interaction
with CDC20 as both the D-box and the phospho Ser98 and
Ser110 motifs are required for APC/CCDC20-dependent destruc-
tion. Our results also suggest that the phospho Ser98 and Ser110
are the major degradation signals (degrons) for CDC20-depen-
315dent degradation.
Stabilization of MEF2C impairs progression through mitosis
and inhibits CYCLIN B1 nuclear accumulation
Our previous results indicate that MEF2C protein undergoes
a mitotic-specific degradation, suggesting that it might have a
Figure 4. Ser98/Ser110 phosphorylation and a proximal conserved D-box are required for CDC20-dependent degradation of MEF2C. (A) Amminoacid
sequence encoded by the a1 isoform. Sequence of a putative D-box near the Ser98 and Ser110 phosphoacceptor sites. Alignment with ClustalW of the
amminoacid sequences encompassing the phosphorylable residues of MEF2C proteins from different species revealed the presence of a conservd D-
box. Amminoacids forming the putative destruction box (D-box) are highlighted in blue, Ser98 and Ser110 in red. The deletion introduced in the MEF2C
D-box mutant (MEF2C D-box del) is indicated. (B) The D-box and Ser98/Ser110 phosphorylation are all necessary for MEF2C degradation. C2 proliferating
myoblasts were co-transfected with an empty vector (EV) or HA-tagged CDC20 and CDH1 vectors along with, alternatively the wild type MEF2C protein
(WT), the D-box deleted mutant (WT D-box DEL), the not-phosphorylable MEF2C 2SA mutant or the MEF2C 2SA mutant deleted of the D-box (2SA D-box
DEL). Cell extracts were analyzed by Western blotting with antibodies against FLAG and HA. Vinculin was used as loading control.
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320 role in the regulation of cell cycle progression. To analyze the
biological relevance of MEF2C cell cycle-regulated degradation
and to verify whether MEF2C stabilization can affect mitosis, we
evaluated the mitotic index of COS cells over-expressing the wild
type or the CDC20-resistant MEF2C 2SA mutant. Overexpres-
325 sion of MEF2C 2SA determined a fold15- reduction of the per-
centage of mitotic cells compared to the wild type protein
(Fig. 5A). These data indicated that degradation of MEF2C is
important for an efficient progression in mitosis. Since CYCLIN
B1 expression, nuclear localization and binding to CDK1 are key
330 events for G2/M transition, we investigated the role of MEF2C
phosphorylation in the regulation of CYCLIN B1. Intriguingly,
MEF2C 2SA over expression in HT29 cells, a colorectal cancer
(CRC) cell line that expresses low levels of endogenous MEF2C
(Fig. 5D), leads to increased cytoplasmic accumulation of
335CYCLIN B1 (Fig. 5B). Furthermore, our data revealed that
ectopic expression of MEF2C induces increased expression of the
genes encoding GADD45B, the cyclin-dependent kinase inhibi-
tor p21Waf1(Cip1 (P21) and 14.3.3 g, all inhibitors of the G2/M
transition (Fig. 5C), and this transcriptional effect is more evi-
340dent with the not degradable 2SA mutant. We then evaluated the
impact of MEF2C level fluctuation on cell divisions in CRC cell
lines. Consistent with the mitotic effect described above, expres-
sion of the stable MEF2C 2SA mutant in HT29 cells, caused a
Figure 5. The ectopic expression of a stable, non phosphorylable mutant of MEF2C can delay cell cycle progression. (A) Overexpression of the MEF2C
2SA mutant is linked to a reduced number of mitotic events. COS-1 cells were transfected with vectors coding for wild type MEF2C (WT) or the not-phos-
phorylable FLAG-MEF2C 2SA mutant. 48 hours later cells were ﬁxed for immunoﬂuorescence analysis and stained with antibodies for phosphorylated
histone H3 and FLAG. Transfected cells were scored for the frequency of mitosis. Histograms show means § SEM of 2 independent experiments. ** rep-
resent P-values  0.01. (B) MEF2C 2SA impairs nuclear translocation of CYCLIN B1. HT29 cells transiently transfected with an empty vector (EV) or the
expression vectors for the wild type or the not-phosphorylable MEF2C 2SA mutant were lysed in order to obtain nuclear and cytoplasmic protein
extracts. The different fractions were analyzed by Western blotting with CYCLIN B1 antibody. Histone H3 and Vinculin antibodies were used as loading
control respectively for nuclear and cytoplasmic fraction. (C) MEF2C regulates the expression of genes encoding inhibitors of the G2/(M)transition. Left
panel, Total RNA was isolated from transfected C2 cells overespressing the wild type or 2SA MEF2C protein. The transcripts of Gadd45b, P21 and 14.3.3 g
genes were ampliﬁed by RT-PCR, PCR products were separated in 8% polyacrylamide gels (left panel). Rplp0 was used as endogenous control. The histo-
gram in the right panel reports the results of the densitometric quantiﬁcation of the bands normalized to Rplp0 and expressed relatively to the empty
vector transfected cells taken as 1. The RT-PCR results are representative of 2 independent experiments. (D) MEF2C is differentially expressed in CRC cell
lines. Total protein extracts from HCT116 and HT29 proliferating cells were analyzed by Western blot with antibody against MEF2C. Vinculin was used as
loading control. (E) MEF2C modulates cell cycle progression in a phosphorylation-dependent manner. HT29 cells were transfected with an empty vector
(EV) or vectors coding for the wild type MEF2C protein or the non-phosphorylable MEF2C 2SA. Twenty-four hours after 0.1 £ 106 cells were plated for
each sample. Cells were then harvested every 24 hours and the number of proliferating cells were counted with an hemacytometer after Trypan blue
staining. The graphs show means § SEM of 4 independent experiments. Statistical signiﬁcance of variation between values obtained at each time points
with MEF2C 2SA and MEF2C WT was calculated. Differences between 2SA and WT are statistically signiﬁcant. ** and *** represent P-values  0.01 and 
0.001 respectively. (F) RNAi knockdown of Mef2c impairs HCT116 proliferation rate. HCT116 cells were transfected with a control siRNA (siCTRL) or a pool
of siRNAs targeting Mef2c (siMef2c) and proliferation rate was evaluated as described in E. The graphs show means § SEM of 4 independent experi-
ments. ** and *** represent P-values  0.01 and  0.001 respectively.
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proliferative defect compared to cells transfected with an empty
345 vector. In contrast, expression of the wild type MEF2C protein
promoted cell proliferation (Fig. 5E). Coherently with these
results, we found that siRNA-mediated silencing of Mef2c in
HCT116 cells, that express high amount of endogenous
MEF2C, impairs their proliferation rate compared to cells trans-
350 fected with a control siRNA (Fig. 5F). Taken together our data
suggest a model where MEF2C controls, directly or indirectly,
the expression of genes of the G2/M checkpoint and its degrada-
tion in the early M Phase is necessary for an efficient progression
of the cell cycle through mitosis and ultimately for cell
355 proliferation.
Discussion
The MEF2C transcription factor has a key role in the control
of muscle-specific genes during skeletal muscle terminal differen-
tiation.5,6,41 Undifferentiated myoblasts express a splice variant
360 of MEF2C, the ubiquitous MEF2C a1 isoform lacking pro-
myogenic activity. The function played by this protein in grow-
ing myoblasts is currently unknown. In the present work, we pro-
vide evidences that MEF2C is involved in the control of cell cycle
progression. First we show that the level of MEF2C fluctuates
365 during the cell cycle in muscle and non-muscle cells, being tar-
geted for degradation early in mitosis by the ubiquitin-
proteasome pathway. Second, we observed that ectopic expres-
sion of a MEF2C a1 protein mutant, resistant to mitotic degra-
dation, impairs cell cycle progression and results in a lower
370 number of cells in mitosis, suggesting a previous unexplored role
for MEF2C a1 in the regulation of cell proliferation. Finally we
observed a modulation of genes that regulate G2/M transition
upon overexpression of MEF2C.
We present several lines of evidence to indicate that both
375 CDC20 and CDH1, the 2 co-activators of APC/C, promote
MEF2C degradation and that mitotic degradation of MEF2C is
mediated by APC/CCdc20. Timely downregulation of MEF2C in
mitosis by APC/CCdc20 requires MEF2C phosphorylation of
Ser98 and Ser110. We found an even level of phosphorylation of
380 the MEF2C a1-specific Ser110 residue during the cell cycle, this
phosphoacceptor site is efficiently phosphorylated by CYCLIN
D1/CDK6 in vitro. Whereas Ser98 is phosphorylated in mitosis
by a yet unknown mitotic kinase. Further, our data indicate that
a priming phosphorylation of Ser110 is necessary for achieving
385 an efficient phosphorylation of Ser98. On the contrary we report
that APC/CCdh1 mediates the down-regulation of MEF2C inde-
pendently from the status of Ser98 and Ser110 phosphorylation.
The APC/CCdh1 ubiquitin ligase normally regulates exit from
mitosis and events in G1. Although overexpression of CDH1
390 results in a strong decrease of MEF2C, the persistence of some of
MEF2C following mitosis exit suggests that a subpopulation of
protein is protected from the CDH1-mediated degradation. We
speculate that phosphorylation on serine and threonine residues,
other than Ser98 and Ser110, might protect MEF2C from APC/
395 CCDH1 mediated degradation as described for other targets of
CDH1.42-45 The functional relevance of CDH1-mediated
degradation will be subject of future studies. Interestingly, we
observed APC/CCdc20 MEF2C degradation in nocodazole-
arrested pseudo-prometaphase cells, when the spindle checkpoint
400(SAC) is actively inhibiting CDC20. The escape from SAC inhi-
bition has been observed also for other APC/C targets such as
CYCLIN A, Nek2A and HoxC10.46-49 One proposed model to
explain the premature degradation of some APC/CCdc20 targets
envisages an increased affinity for CDC20 due to the presence of
405multiple interaction domains in the substrate. Indeed, we found
that APC/CCdc20 -dependent degradation of MEF2C requires a
conserved D-box together with the 2 phospho-motifs pSer98 and
pSer110, located in close proximity to the D-box. Notably, the
D-box and Ser110 residue are located in the protein sequence
410encoded by the ubiquitous alternative exon a1, that we and other
have described to be specifically expressed in proliferating myo-
blasts (see Fig. 2B and Zhang et al, 2014). We previously
reported that pSer98 and pSer110 are binding sites for PIN1,10 a
peptidyL-prolyl cis-trans isomerase that regulates the activities of
415several phosphor-proteins in mitosis.50 A possible role played by
PIN1 in this mechanism warrants future investigations.
Despite the high sequence conservation of the N-terminal
region among MEF2s, we found that the MEF2C a1-specific D-
box, necessary for CDC20-dependent degrading activity, is not
420present in any other member of the family. Although we cannot
exclude a cell cycle regulated expression and/or degradation also
for the other MEF2s, our data prompted us to speculate that the
CDC20-dependent mitotic degradation is a specific feature of
MEF2C and particularly of the a1 isoform. These observations
425together with the recent evidence that individual MEF2s23,51 and
alternative splicing isoforms12 can induce different subsets of
gene during skeletal muscle differentiation and during develop-
ment, lead us to speculate about specific biological function(s)
played by the different members of MEF2 family.
430To date, MEF2C protein function in skeletal muscle and in
other tissues, correlates with their terminal differentiation pro-
grams.5,6,41 The fluctuations of its protein level during the cell
cycle suggest a yet unexplored role in the regulation of cell prolif-
eration. A cell cycle-regulated expression has been described in
435muscle cells also for MYF5 and MYOD, involved in the control
of myoblasts proliferation.31 The observation that the overexpres-
sion of a non phosphorylable mutant, resistant to CDC20-
dependent degradation, impairs mitosis progression means that
it is plausible that MEF2C can have a role in mitosis regulation.
440Although our data do not clarify whether the reduced number of
mitotic events is due to a delayed entrance or a faster exit from
mitosis, we can speculate that MEF2C mutant overexpression
slows down the transition from G2 phase to mitosis. As a matter
of fact, upon overexpression of MEF2C, we observed an induc-
445tion of 14–3–3g, Gadd45b and p21 transcripts, encoding inhibi-
tors of the CYCLIN B1/CDK1 kinase.24,52-56 These genes have a
role in the G2-M checkpoint both in normal cell cycle progres-
sion and in response to DNA damage. We also found that failure
of MEF2C degradation correlates with an increase in the cyto-
450plasmic inactive fraction of CYCLIN B1. It has been recently
reported that MEF2D protein negatively regulates the expression
of Gadd45b and p21 genes and binds to MEF2 sites in their
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promoter sequences in hepatocellular carcinoma (HCC) cell
lines.57 Thus it may be argued that MEF2C induces directly the
455 expression of these G2/M transition inhibitors. In contrast, our
bioinformatic analysis did not reveal any MEF2-site in the pro-
moter region of 14–3–3g, suggesting a possible indirect control
of MEF2C on this gene. In addition to the mitotic effect, we
observed that over-expression of the non-phosphorylable
460 MEF2C mutant in low expressing HT29 CRC cells impairs cell
proliferation possibly as a consequence of the delayed progression
into mitosis, whereas the ectopic expression of wild type MEF2C
increases their proliferation rate. Coherently with these observa-
tions, we found that knockdown of Mef2c expression in high
465 expressing HCT116 cells had a detrimental effect on cell prolifer-
ation. Hence MEF2C degradation might be a “sine qua non”
condition to achieve mitotic progression and, in turn, to allow
cell proliferation. We can hypothesize a positive role of MEF2C
in directly stimulating cell cycle progression by activating the
470 transcription of proliferation-related genes such as c-jun, a well-
known MEF2 target,19 and/or other yet unknown genes likely
related to G1/S transition. This has been recently described by a
gene expression analysis study in muscle cells.23
In conclusion our work reveal a novel function of MEF2C
475 beyond its well known role iN-terminal differentiation. Accord-
ing to the classical model MEF2C does not play any specific
function in growing myoblasts but is necessary to trigger the dif-
ferentiation program upon differentiation stimuli. With this
work we propose that the ubiquitous MEF2C splice variant plays
480 an active role in promoting, directly or indirectly, the expression
of genes that control the G2/M transition thus contributing to
the regulation of cell cycle progression.
Materials and Methods
Cell culture and synchronization
485 C2C12, NIH-3T3, COS-1, HEK293T, HCT116 and HT29
cells were cultured in Dulbecco’s Modified Eagle’s medium, high
glucose, GLUTAMAX (Invitrogen) supplemented with 10%
fetal bovine serum (Gibco) and 100 U/ml Penicillin/Streptomy-
cin (Euroclone). C2 cells were induced to differentiate, when
490 approaching confluence, with DMEM and 2% horse serum
(Hyclone). Cells were cultured at 37C under a 5% CO2 atmo-
sphere. The proteasome inhibitor MG132 (Sigma) was added at
the indicated concentration 5 hours before harvesting the cells.
Transfected COS-1 cells were treated with 25 mM cycloheximide
495 (Sigma) in order to assess protein half-life.
C2 cells were synchronized by culturing them in methionine-
depleted DMEM medium (Sigma) supplemented with 1% fetal
bovine serum, apo-transferrin and sodium selenite (5 mg/ml,
Sigma). C2 cells were treated over-night with aphidicolin
500 (2,5 mg/ml, Sigma) or nocodazole (1 mM, Sigma) to obtain
respectively S or G2/M phase synchronization. Nocodazole
treated cells were subjected to a gentle shake-off in order to col-
lect separately round mitotic cells and G2 adherent cells. Syn-
chronized cells were harvested and DNA distribution analysis
505 was performed after staining with propidium iodide (PI)
(50 mg/ml) with an Epics cytofluorimeter (Beckman Coulter).
Cell cycle distribution was analyzed with WinMDI software.
Proliferation assay
HT29 transfected cells grown in 6 cm plates, were harvested
510by trypsinization 24 hours after transfection and aliquoted in
12wells plates. For the following 72 hours, cells were harvested
every day and the number of proliferating cells was counted with
hematocytometer and Typan Blue staining.
Plasmids and RNA interference
515The FLAG tagged MEF2C full-length cDNA (FLAG-
MEF2C) and the Ser98 (FLAG-MEF2C S98A), Ser 110
(FLAG-MEF2C S110A) or both the serines (FLAG-MEF2C
2SA) mutants were previously described (Magli et al. 2010). The
deletion of the Destruction box (D-box) was obtained by PCR-
520based site-directed mutagenesis using FLAG-MEF2C or FLAG-
MEF2C 2SA as a template, mutations were confirmed by
sequencing. The cDNAs deleted of the encoding
R130XXLXXV137 were cloned into HindIII-BglII digested
pFLAG-CMV (Sigma) with Gibson Assembly Kit (NEB). Plas-
525mid coding for HA-CDC20, HA-CDH1, HA-Ubiquitin and
FLAG-SKP2 were kindly provided by Daniele Guardavaccaro
(Hubrecht Institute). Transient transfections were performed
using Lipofectamine LTX with PLUS Reagent (Invitrogen)
according to manufacturer’s instruction. For siRNA experiments
530C2C12 cells were plated in 6-well plates and transfected with the
indicated amounts of a pool of 3 siRNAs using RNAiMAX (Invi-
trogen) following the manufacturer’s instruction. Cells were ana-
lyzed 48 h after transfection. Silencer siRNAs targeting Cdh1
(74510, 74322, 165926), Cdc20 (171932, 171933, 171934),
535Mef2c (157132, 157133, 157134) and Silencer Negative Control
#3 siRNA were purchased from Ambion (Life Technologies).
Western blot analysis and Immunoprecipitation
Total cell extracts were prepared with RIPA buffer
(50mMTris HCl pH 7.5, 150mMNaCl, 1mMEDTA, 1% Na
540Deoxycholate, 1% Igepal, 0.1% SDS, 1mM DTT) supple-
mented with 1mM phenylmethyl sulfonylflouride (PMSF) and
Proteases Inhibitor Complete cocktail (PIC, Roche). Equal
amounts of protein extracts were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and ana-
545lyzed by Western blot as previously described.12 The following
antibodies were used: mouse monoclonal anti-CYCLIN A (CY-
A1), anti-FLAG (M2) and anti-Vinculin (VIN-11–5) from
Sigma-Aldrich; mouse monoclonal anti-p55 CDC (E-7) from
Santa Cruz Biotechnologies; mouse monoclonal anti-CDH1
550(DH01) from Thermo Scientific; mouse monoclonal Phospho-
Histone H3 (6G3) from Cell signaling; mouse monoclonal anti-
MyHC (MF20) and anti-myogenin (IF5D) from DSHB; rabbit
monoclonal anti-MEF2C (D80C1) from Cell Signaling; rabbit
polyclonal anti-MEF2C (SBS-002) from Sparrow Biosciences;
555rabbit polyclonal anti-HA (H6908) from Sigma-Aldrich; rabbit
polyclonal anti-MYOD (C-20) and anti-MYF5 (C-20) from
Santa Cruz Biotechnologies. Custom polyclonal antibodies
against MEF2C phosphorylated on serine 98 (phosphoSer98) or
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serine 110 (phosphoSer110) were developed in rabbit using syn-
560 thetic phosphorylated MEF2C peptide. The antibodies were
affinity-purified on the immobilized immunizing MEF2C
peptides.
For immunoprecipitation of FLAG tagged proteins, C2C12
cells were harvested 48 hours after transfection and lysed in
565 RIPA buffer supplemented with 1 mM PMSF, PIC, 2,5 mM
sodium fluoride (NaF), 1 mM sodium orthovanadate
(Na3VO4), 0,5 mM EDTA, 10 mM Iodoacetamide, 2 mM
MG132 and 1 mM G5, Ubiquitin Isopeptidase Inhibitor I. Cell
extracts were precleared with Protein G Agarose (KPL) and then
570 incubated with anti-FLAG M2 Affinity Gel (Sigma). Immuno-
precipitates were washed 4 times in RIPA buffer with inhibitors,
eluted by resuspension in Laemmli sample buffer and boiled for
5 minutes. For co-immunoprecipitation HEK293T were treated
with 10 mM MG132 for 5 hours and collected 24 hours after
575 transfection. Total cell extracts were prepared by lysis in Triton
Lysis Buffer (TLB, 50 mM Tris-HCl pH 7.4, 0.25 M NaCl,
1 mM EDTA, 0.1% Triton X-100, 50 mM NaF) supplemented
with 1 mM PMSF, PIC, 1 mM Na3VO4, 1 mM (dithiothrei-
tol). Protein G-beads were coated with mouse monoclonal anti-
580 HA (HA7, Sigma) and cell extracts were precleared as described
above for 1 hours at 4C. Cell extract were then incubated with
protein G-anti HA coated beads for 3 hours at 4C. Immuno-
complex were washed 4 times with TLB with inhibitors and
eluted with Laemmli sample buffer and boiling for 5 minutes.
585 Protein expression in total extracts and immunoprecitated or
coimmunoprecipitated proteins were analyzed by SDS-PAGE
and Western blot as described above.
Extraction of cytoplasmic and nuclear protein
Nuclear and cytoplasmic fraction of HT29 transfected cells
590 were obtained with 2 distinct lysis buffer. Briefly cells were
washed in cold PBS and harvested in Buffer A (10 mM HEPES
pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.15%
Nonidet P40 (NP40) supplemented with 1 mM DTT and PIC).
Cells were homogenized with several passages through a needle
595 26G, nuclei were sedimented by centrifugation and supernatant
containing cytoplasmic protein was conserved. Nuclei were
washed quickly with cold PBS, resuspended in Buffer B (20 mM
HEPES pH 7.9, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA,
0,5% NP 40 supplemented with 1 mM DTT and PIC) and
600 lysed by sonication. Nuclei lysates were clarified by
centrifugation.
Immunofluorescence and mitotic index
Immunostaining of COS-1 cells was performed 48 hours after
transfection as previously described.10 Cellular DNA was stained
605 with Hoeascht 33342 (Sigma) and the following primary anti-
bodies were used: mouse monoclonal anti-FLAG M2 (Sigma)
and rabbit polyclonal anti-phospho Histone H3 (Ser10) (Milli-
pore). For fluorescent detection anti-mouse and anti-rabbit IgG
secondary antibodies conjugated to Alexa Fluor dye (Molecular
610 Probes) were used. All samples were examinated in a Zeiss Axio-
skop 40 fluorescence microscope equipped with an Axiocam
HRC camera for image acquisition. Mitotic index estimation
was performed using Cell Counter plugin of Image J
(http://imagej.nih.gov/ij/) analyzing at last 10 fields for each sam-
615ple for a total amount of about 200 nuclei.
Kinase phosphorylation assay
Kinase phosphorylation assay was performed by ProQinase
GmbH (Freiburg, Germany). Briefly byotinilated peptides
(1 mM) containing phosphorylable Serine 98
620(KGLNGCDSPDPDA) or Serine 110 (ADDSVGHSPESED)
were assayed for phosphorylation in a radiometric assay (33Pan-
Qinase Activity Assay) on a panel of 190 Ser/Thr kinases, using
streptavidin-coated FlashPlate HTS PLUS plates.
RNA extraction and RT-qPCR
625Total RNA was isolated with Total RNA Purification Kit
(Norgen Biotek) and digested with DNaseI (Invitrogen). 500 ng
of RNA were reverse transcribed using Superscript III reverse
transcriptase (Invitrogen) according to manufacturer’s instruc-
tion. The obtained cDNA was qPCR quantified using TaqMan
630Universal Master Mix II (Applied Biosystems) and the PCR ABI
PRISM 7900 HT Sequence Detection System (Applied Biosys-
tems). TaqMan Gene Expression assays for Mef2c transcript and
for the normalizer Rplp0 were purchased from Invitrogen.
For quantification of Gadd45b, P21, 14.3.3g and Mef2c a1
635of a2 isoforms, total RNA was isolated using TRIzol Plus RNA
Purification System (Ambion) 48 h hours after transfection,
cDNA was obtained and their transcripts analyzed with specific
primers. Amplicons were separated in 10% polyacrylamide gel
and identified by Ethidium Bromide staining.
640Student’s t-tests were performed for pairwise comparisons to
determine significant differences between groups.
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